Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 179

Sort by

Sort Order Select

Journal Articles

Development of hyperdiploidy starts at an early age and takes a decade to complete

Mehmet K. Samur, Anil Aktas Samur, Parth Shah, Joseph Park, Mariateresa Fulciniti, Masood A Shammas, Jill Corre, Kenneth C. Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood blood.2024025250.

https://doi.org/10.1182/blood.2024025250

Published: 2024

Includes: Supplemental data

Journal Articles

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Blood (2024) 143 (25): 2612–2626.

https://doi.org/10.1182/blood.2023022777

Published: 2024

Includes: Supplemental data

Journal Articles

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

Zachary R Hunter, Nickolas Tsakmaklis, Kris Richardson, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Ari M Melnick, Steven P Treon

Blood (2023) 142 (Supplement 1): 755.

https://doi.org/10.1182/blood-2023-190825

Published: 2023

Journal Articles

Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies

Giulia Giorgetti, Pamela Becherini, Elena Maroto-Martin, Daniela Fenoglio, Debora Soncini, Claudia Martinuzzi, Santina Bruzzone, Andrea Benzi, Aimable Nahimana, Chiara Rosa Maria Uras, Anaïs Schavgoulidze, Jessica Ng Fong, Roberto M. Lemoli, Nikhil C Munshi, Mariateresa Fulciniti, Michele Cea

Blood (2023) 142 (Supplement 1): 1951.

https://doi.org/10.1182/blood-2023-189439

Published: 2023

Journal Articles

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

Mariateresa Fulciniti, Shuhui Deng, Sanika Dereibal, Vera Joy Weiler, Madhumouli Chatterjee, Jessica Ng Fong, Chandraditya Chakraborty, Rao Prabhala, Masood A. Shammas, Anil Aktas-Samur, Mehmet K. Samur, Annamaria Gulla, Kenneth C. Anderson, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2023-187374

Published: 2023

Journal Articles

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

Kris Richardson, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Steven P Treon

Blood (2023) 142 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2023-190631

Published: 2023

Journal Articles

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

Eugenio Morelli, Anil Aktas-Samur, Domenico Maisano, Claire Gao, Na Liu, Vanessa Favasuli, Marcello Turi, Pietro Folino, Mariateresa Fulciniti, Annamaria Gulla, Kenneth C. Anderson, Mehmet K. Samur, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 640.

https://doi.org/10.1182/blood-2023-185523

Published: 2023

Journal Articles

BCMA-Targeted Bortezomib Nanotherapy (BCMA-BTZ-Nps) Targets Tumor, Enhances Therapeutic Efficacy, Triggers Immunogenic Cell Death, Overcomes Drug Resistance, and Reduces Off-Target Toxicity in Multiple Myeloma (MM)

Debasmita Dutta, Jiye Liu, Kenneth Wen, Keiji Kurata, Mariateresa Fulciniti, Annamaria Gulla, Teru Hideshima, Kenneth C. Anderson

Blood (2023) 142 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2023-188237

Published: 2023

Journal Articles

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Blood (2023) 142 (Supplement 1): 756.

https://doi.org/10.1182/blood-2023-190685

Published: 2023

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Ting Du, Yan Song, Arghya Ray, Xueping Wan, Yao Yao, Mehmet K. Samur, Chen Shen, Johany Penailillo, Tomasz Sewastianik, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Hao Wu, Ruben D. Carrasco, Dharminder Chauhan, Kenneth C. Anderson

Blood (2023) 141 (21): 2599–2614.

https://doi.org/10.1182/blood.2022017897

Published: 2023

Includes: Supplemental data

Journal Articles

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, Stephane Minvielle, Aurore Perrot, Jill Corre, Philippe Moreau, Anjan Thakurta, Giovanni Parmigiani, Kenneth C. Anderson, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2023) 141 (14): 1724–1736.

https://doi.org/10.1182/blood.2022017094

Published: 2023

Includes: Supplemental data

Journal Articles

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Blood (2023) 141 (4): 391–405.

https://doi.org/10.1182/blood.2022016892

Published: 2023

Includes: Supplemental data

Journal Articles

Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors

Mehmet K. Samur, Nathan Martin, Ethan Thompson, Mariateresa Fulciniti, Anil Aktas-Samur, Shari Kaiser, Nikhil C Munshi

Blood (2022) 140 (Supplement 1): 2106–2107.

https://doi.org/10.1182/blood-2022-168903

Published: 2022

Journal Articles

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Yao Yao, Jessica Fong Ng, Woojun D Park, Mehmet K. Samur, Eugenio Morelli, Nicholas P Kwiatkowski, Jessica Encinas Mayoral, Zuzana Chyra, Yan Xu, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Charles Y Lin, Nikhil C Munshi, Mariateresa Fulciniti

Blood (2022) 140 (Supplement 1): 9955–9956.

https://doi.org/10.1182/blood-2022-163811

Published: 2022

Journal Articles

Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma

Annamaria Gulla, Eugenio Morelli, Mehmet K. Samur, Megan Johnstone, Cirino Botta, Delaney Vinaixa, Marcello Turi, Mariateresa Fulciniti, Kenneth Wen, Selma Cifric, Srikanth Talluri, Giada Bianchi, Rao Prabhala, Paul G. Richardson, Dharminder Chauhan, Ruben D. Carrasco, Teru Hideshima, Nikhil C Munshi, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 7114–7115.

https://doi.org/10.1182/blood-2022-162653

Published: 2022

Journal Articles

Somatic Changes Prior to the Development of Hyperdiploidy Expose Mutation Accumulation Rate and Activated Processes in Multiple Myeloma

Thomas C. Smits, Anil Aktas-Samur, Romain Lannes, Mariateresa Fulciniti, Masood A. Shammas, Jill Corre, Giovanni Parmigiani, Herve Avet-Loiseau, Nikhil C Munshi, Mehmet K. Samur

Blood (2022) 140 (Supplement 1): 7062–7063.

https://doi.org/10.1182/blood-2022-168837

Published: 2022

Journal Articles

26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma

Ting Du, Xueping Wan, Arghya Ray, Yao Yao, Ruben D. Carrasco, Mariateresa Fulciniti, Nikhil C Munshi, Dharminder Chauhan, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 8853–8854.

https://doi.org/10.1182/blood-2022-163749

Published: 2022

Journal Articles

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1551–1552.

https://doi.org/10.1182/blood-2022-167604

Published: 2022

Journal Articles

In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis

Anil Aktas-Samur, Jill Corre, Laure Buisson, Mariateresa Fulciniti, Kenneth C. Anderson, Mehmet K. Samur, Nikhil C Munshi, Herve Avet-Loiseau

Blood (2022) 140 (Supplement 1): 4362–4363.

https://doi.org/10.1182/blood-2022-168943

Published: 2022

NARROW

Development of hyperdiploidy starts at an early age and takes a decade to complete

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

BCMA-Targeted Bortezomib Nanotherapy (BCMA-BTZ-Nps) Targets Tumor, Enhances Therapeutic Efficacy, Triggers Immunogenic Cell Death, Overcomes Drug Resistance, and Reduces Off-Target Toxicity in Multiple Myeloma (MM)

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma

Somatic Changes Prior to the Development of Hyperdiploidy Expose Mutation Accumulation Rate and Activated Processes in Multiple Myeloma

26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only